World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
45664
World Ranking
8795
National Ranking
4532

Overview

Xavier Leleu is affiliated with Harvard University in the United States and has a significant presence in medical research, particularly focused on hematology and oncology. Their work extensively covers multiple myeloma, including its treatments and underlying biological mechanisms.

The main fields of study for Leleu include Medicine and Biochemistry, Genetics and Molecular Biology. Within these, their subfields of expertise are Hematology, Molecular Biology, Oncology, Genetics, and Pathology and Forensic Medicine.

Leleu's research topics prominently feature:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Cancer Mechanisms and Therapy

The scientist has contributed to several high-impact recent papers, including:

  • "Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma" (2023, New England Journal of Medicine)
  • "Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study" (2020, The Lancet)
  • "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" (2023, New England Journal of Medicine)
  • "Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial" (2021, The Lancet)
  • "Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial" (2021, The Lancet Oncology)

Leleu has frequent collaborative relationships with multiple researchers, including:

  • Philippe Moreau
  • Aurore Perrot
  • Meletios Α. Dimopoulos
  • Thierry Façon
  • Cyrille Touzeau

The scientist's work has been published extensively in notable medical journals and venues, with frequent contributions to:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere
  • Blood Cancer Journal

Leleu's extensive publication record includes over 700 works, primarily in medicine with strong emphasis on hematology and multiple myeloma research. Their research pursuits continue advancing understanding in cancer biology, immunotherapy approaches such as CAR-T cell therapy, and pharmacological strategies targeting hematologic malignancies.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

    Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Michel Attal;Paul G. Richardson;S. Vincent Rajkumar;Jesus San-Miguel

  • Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

    Brian A. Walker;Eileen M. Boyle;Christopher P. Wardell;Alex Murison

  • Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

    Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu

  • Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

    Hervé Avet-Loiseau;Xavier Leleu;Murielle Roussel;Philippe Moreau

  • High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

    Arnaud Jaccard;Philippe Moreau;Véronique Leblond;Xavier Leleu

  • Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study

    Jean-Luc Harousseau;Michel Attal;Xavier Leleu;Jacques Troncy

  • Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

    Meletios A. Dimopoulos;Dominik Dytfeld;Sebastian Grosicki;Philippe Moreau

  • CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

    Abdel Kareem Azab;Judith M. Runnels;Costas Pitsillides;Anne-Sophie Moreau

  • Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

    Philippe Moreau;Thierry Facon;Xavier Leleu;Nadine Morineau

  • International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

    Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

  • Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

    Thierry Facon;Hervé Avet-Loiseau;Gaëlle Guillerm;Philippe Moreau

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196)

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

Frequent Co-Authors

Thierry Facon
Thierry Facon Centre Hospitalier Régional et Universitaire de Lille
Irene M. Ghobrial
Irene M. Ghobrial Harvard University
Philippe Moreau
Philippe Moreau University of Nantes
Denis Caillot
Denis Caillot Grenoble Alpes University
Steven P. Treon
Steven P. Treon Harvard University
Michel Attal
Michel Attal Janssen (Belgium)
Paul G. Richardson
Paul G. Richardson Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to a traditional medical degree, there are multiple online options for those seeking careers in healthcare. If you’re interested in healthcare leadership, consider one of the cheapest online mha programs. These programs provide essential management skills and open doors to administrative roles.

For nurses aiming to reach the highest level of practice, pursuing one of the cheapest dnp online programs can be a flexible and affordable way to earn a Doctor of Nursing Practice degree. DNP graduates often lead teams, influence healthcare policy, and improve patient outcomes.

Those interested in the pharmaceutical field may benefit from an online pharmacy degree. These degrees prepare you for diverse roles, from clinical pharmacy to research and education.

Technology-minded students can look into online schools for health information management. This field plays a critical role in healthcare data, compliance, and IT security.

Exploring these related online degrees can expand your career options and provide alternative pathways into the growing healthcare industry.

Best Scientists Citing Xavier Leleu

Trending Scientists